You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 16, 2025

GLASSIA Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: GLASSIA
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for GLASSIA
Recent Clinical Trials for GLASSIA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
OctapharmaPhase 2
Baxalta US Inc.Phase 2/Phase 3
Baxalta now part of ShirePhase 2/Phase 3

See all GLASSIA clinical trials

Pharmacology for GLASSIA
Mechanism of ActionTrypsin Inhibitors
Established Pharmacologic ClassHuman alpha-1 Proteinase Inhibitor
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for GLASSIA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for GLASSIA Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for GLASSIA Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Biologic Drug: GLASSIA

Introduction to GLASSIA

GLASSIA is an alpha-1 antitrypsin (AAT) therapy developed by Kamada Pharmaceuticals, designed to treat Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder that can lead to lung disease and liver disease.

Market Context of Biologic Drugs

The biologics market is experiencing significant growth, driven by factors such as the rising burden of chronic diseases, technological advancements, and the increasing adoption of biosimilars. The global biologics market was valued at USD 461.74 billion in 2022 and is expected to grow at a CAGR of 10.3% from 2023 to 2030[1][3].

GLASSIA's Position in the Biologics Market

GLASSIA is part of the broader category of biologic therapies that are gaining traction due to their targeted and effective treatment mechanisms. Here are some key points that highlight GLASSIA's position:

Regulatory Approvals

GLASSIA has received significant regulatory approvals, including FDA approval to manufacture the drug at Kamada's facility in Israel. This approval has positively impacted the facility's utilization and efficiency[2].

Clinical Trials and Development

Kamada is also progressing with its InnovAATe clinical trial for the inhaled Alpha-1 Antitrypsin (AAT) therapy, which has enrolled 60 patients to date. The independent Data Safety Monitoring Board (DSMB) has recommended the study's continuation without modification, indicating promising results[2].

Financial Performance of Kamada Pharmaceuticals

To understand the financial trajectory of GLASSIA, it is essential to look at the financial performance of Kamada Pharmaceuticals.

Revenue Growth

In the first quarter of 2023, Kamada reported total revenues of $30.7 million, representing a 9% increase year-over-year compared to $28.1 million in the first quarter of 2022. The gross profit and gross margins were $11.8 million and 39%, respectively, in the first quarter of 2023[2].

Segmental Revenue

Kamada's revenue is segmented into proprietary products and distribution. The proprietary products segment, which includes GLASSIA, has shown steady growth. For instance, in 2022, the proprietary products segment contributed significantly to the company's revenue, with a gross profit margin of around 40% before adjustments for intangible assets depreciation[2].

Research and Development Expenses

Kamada has been investing in research and development, with expenses amounting to $3.231 million in the first quarter of 2023. This investment is crucial for the ongoing clinical trials and development of GLASSIA and other biologic products[2].

Market Drivers for GLASSIA

Several factors are driving the market growth for GLASSIA and similar biologic therapies:

Increasing Burden of Chronic Diseases

The rising prevalence of chronic diseases such as AATD is a significant driver. As the population ages and the incidence of genetic diseases increases, the demand for targeted therapies like GLASSIA is expected to rise[1][3].

Technological Advancements

Advancements in biotechnology, including the development of more efficient drug delivery systems and manufacturing processes, are enhancing the efficacy and accessibility of biologic drugs like GLASSIA[3][4].

Regulatory Approvals and Reimbursement Policies

Favorable regulatory approvals and reimbursement policies, especially in regions like North America, are crucial for the market growth of biologic drugs. The FDA approval for GLASSIA manufacturing at Kamada's facility is a testament to this[1][2].

Regional Outlook

North America

North America holds the largest revenue share in the biologics market, driven by the high prevalence of chronic diseases, the presence of leading biopharmaceutical companies, and favorable reimbursement policies. GLASSIA, being approved in the U.S., benefits from these factors[1].

Asia Pacific

The Asia Pacific region is also expected to grow significantly, driven by the increasing burden of diseases and the adoption of biosimilars. While GLASSIA's primary market is currently in North America, expanding into the Asia Pacific could offer additional growth opportunities[1].

Competitive Landscape

The biologics market is highly competitive, with several major players such as Eli Lilly & Company, Samsung Biologics, and Pfizer Inc. Kamada Pharmaceuticals, while smaller, has a niche position with products like GLASSIA and is leveraging strategic agreements and partnerships to enhance its market presence[1][2].

Manufacturing and Contract Manufacturing

The biologics contract manufacturing market is growing rapidly, with a projected CAGR of 12.2% during the forecast period. Companies like Samsung Biologics are expanding their contract manufacturing deals to support the production of biologic drugs, including those similar to GLASSIA[4].

Key Takeaways

  • Regulatory Approvals: GLASSIA has received significant regulatory approvals, including FDA approval for manufacturing at Kamada's facility in Israel.
  • Clinical Trials: The InnovAATe clinical trial for inhaled AAT therapy is progressing well, with positive recommendations from the DSMB.
  • Financial Growth: Kamada Pharmaceuticals has shown steady revenue growth, with a focus on proprietary products like GLASSIA.
  • Market Drivers: The increasing burden of chronic diseases, technological advancements, and favorable regulatory approvals are driving the market growth for GLASSIA.
  • Regional Opportunities: North America is a key market, but the Asia Pacific region offers potential for future growth.

FAQs

1. What is GLASSIA used for? GLASSIA is an alpha-1 antitrypsin (AAT) therapy used to treat Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder that can lead to lung and liver diseases.

2. Who is the manufacturer of GLASSIA? GLASSIA is manufactured by Kamada Pharmaceuticals.

3. What are the key regulatory approvals for GLASSIA? GLASSIA has received FDA approval for manufacturing at Kamada's facility in Israel.

4. How is the market for biologic drugs like GLASSIA expected to grow? The biologics market is expected to grow at a CAGR of 10.3% from 2023 to 2030, driven by factors such as the rising burden of chronic diseases and technological advancements.

5. What are the main drivers for the growth of GLASSIA in the market? The main drivers include the increasing burden of chronic diseases, technological advancements, and favorable regulatory approvals and reimbursement policies.

Cited Sources

  1. Grand View Research: Biologics Market Size, Share & Growth Analysis Report, 2030
  2. Kamada Pharmaceuticals: Q1 2023 Financial Report
  3. BioSpace: Biologics Market Size to Reach USD 699.5 Billion by 2032
  4. Transparency Market Research: Biologics Contract Manufacturing Market Insights, 2021-2031
Last updated: 2024-12-18

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.